SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway. Xue Z, Wang J, Wang Z, Liu J, et al. BMC Cancer 2023;23:589.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Xue Z, Wang J, Wang Z, Liu J, et al. SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway. BMC Cancer 2023;23:589.
PMID: 37365560